Search

Your search keyword '"R, Creech"' showing total 4 results
Start Over Author "R, Creech" Journal seminars in oncology
4 results on '"R, Creech"'

1. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response

Author

D S, Ettinger, J, Allegra, J R, Bertino, P, Bonomi, H, Browder, P, Byrne, J, Carpenter, R, Catalano, R, Creech, and B, Dana

Subjects
Random Allocation, Tamoxifen, Neoplasms, Hormone-Dependent, Receptors, Estrogen, Megestrol Acetate, Humans, Antineoplastic Agents, Breast Neoplasms, Female, Receptors, Cell Surface, Megestrol, Middle Aged, Receptors, Progesterone
Abstract

This report describes the preliminary results from a randomized study comparing megestrol acetate with tamoxifen in the treatment of postmenopausal women with advanced breast cancer, correlating estrogen receptors (ER) and progesterone receptor (PgR) status with response. Patients received megestrol acetate (40 mg) orally four times daily or tamoxifen (10 mg) orally twice daily. If the initial therapy failed, patients were crossed over to the alternate treatment. Of 197 patients entered in the study, 190 were considered evaluable. The overall response rates were 35% with megestrol acetate and 42% with tamoxifen. Twenty-three percent (7/30) of patients responded to megestrol acetate after being crossed over from tamoxifen, while 22% (6/27) responded to tamoxifen after being crossed over from megestrol acetate. Response did not correlate significantly with combined receptor (ie, ER plus PgR) levels. A significant trend was seen between ER level and response only in the tamoxifen group. There was no association between PgR levels and response for either tamoxifen or megestrol acetate.

Published
1986

2. Metastatic breast cancer: preliminary results with oral hormonal therapy

Author

J C, Allegra, J, Bertino, P, Bonomi, P, Byrne, J, Carpenter, R, Catalano, R, Creech, B, Dana, H, Durivage, and L, Einhorn

Subjects
Adult, Clinical Trials as Topic, Random Allocation, Tamoxifen, Megestrol Acetate, Administration, Oral, Humans, Breast Neoplasms, Female, Megestrol, Middle Aged, Neoplasm Metastasis, Aged
Abstract

Hormonal therapy is very effective in the treatment of patients with metastatic breast cancer. Response to various therapies leads to improved quality of life and prolonged survival. This clinical trial compared two commonly utilized additive hormonal agents, tamoxifen citrate and megestrol acetate (Megace). Preliminary data indicate equal efficacy and equal toxicity of these two hormones and suggests that both are suitable for first-line hormonal treatment of stage IV breast cancer.

Published
1985

3. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response.

Author

Ettinger DS, Allegra J, Bertino JR, Bonomi P, Browder H, Byrne P, Carpenter J, Catalano R, Creech R, and Dana B

Subjects
Breast Neoplasms metabolism, Female, Humans, Megestrol therapeutic use, Megestrol Acetate, Middle Aged, Neoplasms, Hormone-Dependent metabolism, Random Allocation, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Megestrol analogs & derivatives, Neoplasms, Hormone-Dependent drug therapy, Receptors, Cell Surface metabolism, Tamoxifen therapeutic use
Abstract

This report describes the preliminary results from a randomized study comparing megestrol acetate with tamoxifen in the treatment of postmenopausal women with advanced breast cancer, correlating estrogen receptors (ER) and progesterone receptor (PgR) status with response. Patients received megestrol acetate (40 mg) orally four times daily or tamoxifen (10 mg) orally twice daily. If the initial therapy failed, patients were crossed over to the alternate treatment. Of 197 patients entered in the study, 190 were considered evaluable. The overall response rates were 35% with megestrol acetate and 42% with tamoxifen. Twenty-three percent (7/30) of patients responded to megestrol acetate after being crossed over from tamoxifen, while 22% (6/27) responded to tamoxifen after being crossed over from megestrol acetate. Response did not correlate significantly with combined receptor (ie, ER plus PgR) levels. A significant trend was seen between ER level and response only in the tamoxifen group. There was no association between PgR levels and response for either tamoxifen or megestrol acetate.

Published
1986

4. Metastatic breast cancer: preliminary results with oral hormonal therapy.

Author

Allegra JC, Bertino J, Bonomi P, Byrne P, Carpenter J, Catalano R, Creech R, Dana B, Durivage H, and Einhorn L

Subjects
Administration, Oral, Adult, Aged, Clinical Trials as Topic, Female, Humans, Megestrol adverse effects, Megestrol therapeutic use, Megestrol Acetate, Middle Aged, Neoplasm Metastasis, Random Allocation, Tamoxifen adverse effects, Breast Neoplasms drug therapy, Megestrol analogs & derivatives, Tamoxifen therapeutic use
Abstract

Hormonal therapy is very effective in the treatment of patients with metastatic breast cancer. Response to various therapies leads to improved quality of life and prolonged survival. This clinical trial compared two commonly utilized additive hormonal agents, tamoxifen citrate and megestrol acetate (Megace). Preliminary data indicate equal efficacy and equal toxicity of these two hormones and suggests that both are suitable for first-line hormonal treatment of stage IV breast cancer.

Published
1985

Catalog

Books, media, physical & digital resources
See catalog results